7,575 Shares in Biogen Inc. $BIIB Bought by North Dakota State Investment Board

North Dakota State Investment Board acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,575 shares of the biotechnology company’s stock, valued at approximately $1,333,000.

Other large investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC increased its position in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares during the period. CVA Family Office LLC increased its holdings in shares of Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 71 shares during the period. Davis Investment Partners LLC increased its holdings in shares of Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares during the period. Optas LLC increased its holdings in shares of Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its stake in Biogen by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 89 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $190.56 on Wednesday. The business’s 50 day moving average is $185.40 and its 200-day moving average is $180.14. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $28.13 billion, a PE ratio of 20.45, a PEG ratio of 1.69 and a beta of 0.19. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts predict that Biogen Inc. will post 14.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Rothschild & Co Redburn raised their target price on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Truist Financial decreased their price objective on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research report on Monday, April 13th. The Goldman Sachs Group raised their price objective on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Finally, Royal Bank Of Canada raised their price target on Biogen from $213.00 to $222.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Biogen presently has an average rating of “Moderate Buy” and an average target price of $215.62.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.